[{"data":1,"prerenderedAt":168},["ShallowReactive",2],{"drug-sevelamer":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":36,"contraindications":61,"warnings":71,"renal":72,"monitoring":73,"interactions":74,"review":75,"examples":78,"atc":84,"iran":86,"links":110,"populations":128,"usApproval":163},"sevelamer",1,{"fa":7,"en":8},"سولامر","Sevelamer carbonate","various",{"fa":11,"en":12},"باندر فسفات","Phosphate binder",[14],{"name":15,"market":16},"Renvela","US",[18,19,20,7],"renvela","renagel","رنولا",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"tab-800","tablet","oral","800 mg tablet",{"amount":28,"unit":29,"perUnit":24,"scored":30},800,"mg",false,[16],[33],{"source":34,"section":35},"fda-renvela","3",[37],{"id":38,"disease":39,"label":40,"population":43,"type":47,"unit":29,"dose":48,"refs":51,"notes":54},"std","hyperphosphatemia",{"fa":41,"en":42},"فسفات بالا در دیالیز — ۰٫۸ تا ۱٫۶ g سه بار در روز با غذا","Hyperphosphataemia on dialysis — 0.8–1.6 g three times daily with meals",{"minAge":44},{"value":45,"unit":46},18,"year","fixed",{"perDose":28,"perDoseMax":49,"dosesPerDay":50},1600,3,[52],{"source":34,"section":53},"2.1, Table 1",[55],{"text":56,"refs":59},{"fa":57,"en":58},"فسفر ۵٫۵ تا ۷٫۵: ۰٫۸ g؛ ۷٫۵ و بیشتر: ۱٫۶ g سه بار با غذا. هر ۲ هفته ۰٫۸ g در هر وعده افزایش تا رسیدن به هدف.","Phosphorus >5.5–\u003C7.5: 0.8 g; ≥7.5: 1.6 g three times daily with meals. Titrate by 0.8 g per meal every 2 weeks to target.",[60],{"source":34,"section":53},[62],{"id":63,"severity":64,"text":65,"refs":68},"ci","block",{"fa":66,"en":67},"انسداد روده؛ حساسیت به سولامر.","Bowel obstruction; hypersensitivity to sevelamer.",[69],{"source":34,"section":70},"4",[],[],[],[],{"status":76,"reviewer":77,"date":77},"unverified",null,[79],{"regimen":38,"formulation":23,"input":80,"expect":83},{"ageYears":81,"weightKg":82},55,70,{"perDose":28,"upperPerDose":49},[85],"V03AE02",{"status":87,"forms":88,"refs":105},"registered",[89,93,97,101],{"code":90,"en":91,"fa":92},"04000","SEVELAMER 800MG TAB","قرص سولامر ۸۰۰ میلی‌گرم",{"code":94,"en":95,"fa":96},"21183","SEVELAMER CARBONATE 800MG TAB","قرص سولامر کربنات ۸۰۰ میلی‌گرم",{"code":98,"en":99,"fa":100},"50111","SEVELAMER 2.5 gr Powder For Solution","پودر سولامر ۲٫۵ گرم",{"code":102,"en":103,"fa":104},"52717","SEVELAMER CARBONATE POWDER, FOR SUSPENSION ORAL 800 mg","سوسپانسیون خوراکی سولامر کربنات ۸۰۰ میلی‌گرم",[106],{"source":107,"section":108,"url":109},"darooyab-generic","G-1978\u002FSevelamer","https:\u002F\u002Fwww.darooyab.ir\u002FG-1978\u002FSevelamer",[111,115,119,123,126],{"kind":112,"url":113,"label":114},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022318","NDA022318",{"kind":116,"url":117,"label":118},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=e6328460-a57b-450b-a48c-6dcd4b476360","FDA Renvela",{"kind":120,"url":121,"label":122},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa601248.html","Sevelamer",{"kind":124,"url":125,"label":85},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=V03AE02",{"kind":127,"url":109,"label":122},"darooyab",{"pregnancy":129,"lactation":138,"pediatric":146,"geriatric":155},{"level":130,"text":131,"quote":134,"refs":135},"ok",{"fa":132,"en":133},"برچسب: جذب سیستمیک ناچیز؛ مواجهه جنین انتظار نمی‌رود.","Label: minimal systemic absorption; fetal exposure not expected.","Risk Summary Sevelamer carbonate is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug.",[136],{"source":34,"section":137},"8.1",{"level":130,"text":139,"quote":142,"refs":143},{"fa":140,"en":141},"برچسب: مواجهه شیرخوار انتظار نمی‌رود.","Label: infant exposure not expected.","Risk Summary Renvela is not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to result in exposure of the child to Renvela.",[144],{"source":34,"section":145},"8.2",{"level":147,"text":148,"quote":151,"refs":152},"caution",{"fa":149,"en":150},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and efficacy of Renvela in lowering serum phosphorus levels was studied in patients 6 years of age and older with CKD.",[153],{"source":34,"section":154},"8.4",{"level":147,"text":156,"quote":159,"refs":160},{"fa":157,"en":158},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.",[161],{"source":34,"section":162},"8.5",{"kind":164,"refs":165,"id":114},"NDA",[166],{"source":34,"section":167},"SPL approval \u002F marketing category",1792111467956]